iECURE, a gene editing company started by University of Pennsylvania scientist Dr. Jim Wilson, has received FDA approval to test a form of gene editing in infants for the first time in the United States.
View Full Post
Posted on Apr 09, 2024
| Tagged:
News
What is the power of the humble bicycle? For Dr. Jim Wilson, a rare disease researcher at the University of Pennsylvania, the bicycle unleashed inspiration. Wilson turned his love of cycling into an annual event that has channeled $17 million into rare disease research.
View Full Post
Gene therapy adeno-associated viruses (AAVs) - viruses that can be engineered to deliver DNA to target cells - are unlikely to cause cancer-triggering insertions in humans or monkeys and may contribute to long-term efficacy, according to new research from the University of Pennsylvania’s Gene Therapy Program (GTP).
View Full Post
Posted on Nov 06, 2023
| Tagged:
News
The Foundation for Angelman Syndrome Therapeutics (FAST), a non-profit organization, has entered into an exclusive global collaborative research and development agreement with the University of Pennsylvania to develop an investigational adeno-associated virus (AAV) gene therapy for Angelman syndrome.
View Full Post
Posted on Oct 17, 2023
| Tagged:
News
Nine researchers from the University of Pennsylvania’s Gene Therapy Program (GTP) presented abstracts highlighting their translational science and discovery research on gene therapy, gene editing, and adeno-associated virus (AAV) vector technology at the American Society of Cell and Gene Therapy (ASGCT)’s 26th Annual Meeting.
View Full Post
Posted on May 16, 2023
| Tagged:
News